All patients
age >= 55 yr age >= 65 yr critical disease
convalescent plasma treatment in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
0.68 [0.35 ; 1.33 ] O’Donnell, 2021, PlasmAr, 2020 2 37% 556 low not evaluable deathsdetailed results ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
0.79 [0.37 ; 1.69 ] ILBS-COVID-02 (Bajpai M), 2020, O’Donnell, 2021, PlasmAr, 2020 3 42% 586 low not evaluable deaths (time to event analysis only)detailed results PlasmAr, 2020 0.93 [0.47; 1.85]
0.93 [0.47 ; 1.85 ] PlasmAr, 2020 1 0% 334 NA not evaluable clinical improvementdetailed results O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
1.03 [0.71 ; 1.50 ] O’Donnell, 2021, PlasmAr, 2020 2 44% 556 low not evaluable clinical improvement (28-day)detailed results O’Donnell, 2021 1.38 [0.73; 2.61]
1.38 [0.73 ; 2.61 ] O’Donnell, 2021 1 0% 223 NA not evaluable clinical improvement (time to event analysis only)detailed results O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
1.08 [0.88 ; 1.33 ] O’Donnell, 2021, PlasmAr, 2020 2 0% 557 low not evaluable mechanical ventilationdetailed results O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
1.03 [0.53 ; 2.00 ] O’Donnell, 2021, PlasmAr, 2020 2 0% 556 low not evaluable off oxygenationdetailed results ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88]
0.26 [0.02 ; 2.88 ] ILBS-COVID-02 (Bajpai M), 2020 1 0% 29 NA not evaluable serious adverse eventsdetailed results O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
0.95 [0.44 ; 2.05 ] O’Donnell, 2021, PlasmAr, 2020 2 70% 552 low not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-27 18:55 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 538,957
- roots T: 290